- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02241590
Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus
Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China. The effective inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV, and the anti-fibrotic strategy focusing on the regulation of hepatic extracellular matrix is still required and hopefully improve the efficacy of anti-virals for liver fibrotic patients with HBV, especially is necessary for in the patients with advance fibrosis stage ie. liver cirrhosis. Fuzheng Huayu has been found to enhance the degradation of collagens in fibrotic liver and have a good action against liver fibrosis in patients with chronic hepatitis B. However, there are no high quality clinical evidences which can demonstrate if the combination of anti-viral and anti-fibrotic therapy can improve the reversion of liver cirrhosis due to HBV.
The primary objective of this study is to establish the safety and efficacy of the combination of Entecavir and Fuzheng Huayu for the reversion of liver fibrosis in patients with liver cirrhosis due to HBV.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Recruiting
- China-Japan Friendship Hospital
-
Beijing, China
- Recruiting
- Beijing Ditan Hospital Capital Medical University
-
Beijing, China
- Recruiting
- Beijing Youan Hospital Capital Medical University
-
Shanghai, China
- Recruiting
- Shanghai Zhongshan Hospital
-
Shanghai, China
- Recruiting
- Ruijin Hospital
-
Shanghai, China, 201203
- Recruiting
- ShuGuang Hospital
-
Contact:
- Zhimin Zhao, PhD
- Phone Number: 8621-20256409
- Email: kilorair@sina.com
-
Shenzhen, China
- Recruiting
- Shenzhen Third People's Hospital
-
-
Guangxi
-
Nanning, Guangxi, China
- Recruiting
- Guangxi Ruikang Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China
- Recruiting
- The Fifth Hospital of Shijiazhuang
-
-
Henan
-
Anyang, Henan, China
- Recruiting
- The Fifth People's Hospital of Anyang
-
-
Hubei
-
Jingmen, Hubei, China
- Recruiting
- Jingmen NO.1 People's Hospital
-
Wuhan, Hubei, China
- Recruiting
- Tongji Hospital
-
Wuhan, Hubei, China
- Recruiting
- Hubei Hospital of TCM
-
-
Hunan
-
Changsha, Hunan, China
- Recruiting
- The first affiliated hospital of Hunan University of TCM
-
-
Jiangsu
-
Huai'an, Jiangsu, China
- Recruiting
- Huai'an No. 4 People's Hospital
-
Suzhou, Jiangsu, China
- Recruiting
- The Fifth People's Hospital of Suzhou
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Recruiting
- The Ninth Hospital of Nanchang
-
-
Ningxia
-
Yinchuan, Ningxia, China
- Recruiting
- Ningxia People's Hospital
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Affiliated Hospital of Shandong Univercity of TCM
-
-
Zhejiang
-
Wenzhou, Zhejiang, China
- Recruiting
- Wenzhou Central Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- More than 6 months history of serum positive HBsAg
- Positive HBV-DNA
- Age 18-60
- Ishak fibrosis score of the biopsy within 6 months ≥5, no anti-virus or anti-fibrosis drug was taken within 6 months.
- Child-Pugh<7 (Stage A)
- The patient or the patient's guardian agrees to participate the trial and sign the informed Consent Form.
Exclusion Criteria:
- Primary Lamivudine, Adefovir dipivoxil and Entecavir resistance
- Decompensated liver cirrhosis
- HCC
- Liver histology conforming to other chronic liver diseases, such as moderate or severe non-alcoholic fatty liver disease(more than 1/3 steatosis in liver ), chronic hepatitis C, chronic hepatitis D, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, inherited metabolic liver disease, drug or toxic induced liver injury, parasitic infections, alcoholic liver disease.
- Have psychiatric history or uncontrollable epilepsy patient.
- Uncontrollable diabetic patient
- History of hemoglobin disease (such as alpha- or beta-thalassemia, sickle cell disease, spherocytosis) or patients with toxic or autoimmune hemolytic anemia.
- Severe background disease like chronic respiratory failure, circulatory failure, kidney failure etc.
- In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow transplantation and stem cell transplantation.
- Immunocompromised patients: such as HIV infection or take immunosuppressor or glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3 months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer chemotherapy) and radioactive therapy.
- Gestation or lactation period women and women who plan to get pregnant during the study period.
- Patient who are allergy to the experimental drug.
- Using history of anti-viral or anti-fibrosis drug within 6 months.
- Patients who are participating other trials.
- Other situation where PI thinks the patient should be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Entecavir + Placebo
Tablet with Entrcavir+ Tablet with starch
|
The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
|
Experimental: Entecavir + Fuzheng Huayu Tablet
Tablet with Entrcavir+ Tablet with Fuzheng Huayu
|
The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of liver fibrosis
Time Frame: 48 weeks
|
The collagen of liver tissue from 48 week post-treatment patients was stained.
3 pathologists read the slides independently and score the slides with Ishak system.
If the Ishak score decrease 1 or more than 1 score, then it is recorded as regression.
|
48 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Fibrosis
- Hepatitis B
- Hepatitis
- Hepatitis A
- Liver Cirrhosis
- Anti-Infective Agents
- Antiviral Agents
- Entecavir
Other Study ID Numbers
- SGHLC20140818001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis Due to Hepatitis B Virus
-
Tianjin Second People's HospitalNot yet recruitingGastroesophageal Varices | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis CChina
-
Asian Institute Of Medical SciencesUnknownCirrhosis Due to Hepatitis BPakistan
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Renmin Hospital of Wuhan UniversityVCANBIO Cell & Gene Engineering Corporation, Ltd; Wuhan Optics Valley Zhongyuan...RecruitingCirrhosis Due to Hepatitis BChina
-
Sun Yat-sen UniversityRecruitingCirrhosis of Liver Due to Hepatitis B (Disorder)China
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
FibroGenTerminatedLiver Fibrosis Due to Chronic Hepatitis B InfectionHong Kong, Thailand
-
Universidade Federal do Rio de JaneiroCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Oswaldo Cruz... and other collaboratorsUnknownLiver Cirrhosis Due to Virus C Chronic HepatitisBrazil
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... and other collaboratorsUnknownHepatitis B Virus Related CirrhosisChina
Clinical Trials on Entecavir + Placebo
-
Sunshine Lake Pharma Co., Ltd.Suspended
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis BChina
-
Assembly BiosciencesTerminatedChronic Hepatitis BChina, Korea, Republic of, United States, United Kingdom, Australia, Canada, Hong Kong, Taiwan, New Zealand
-
Fu-Sheng WangJinan Military General HospitalCompletedChronic Hepatitis BChina
-
Chongqing Jiachen Biotechnology Ltd.Third Military Medical UniversityCompletedChronic Hepatitis BChina
-
FibroGenTerminatedLiver Fibrosis Due to Chronic Hepatitis B InfectionHong Kong, Thailand
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People... and other collaboratorsCompleted
-
Aucta Pharmaceuticals, IncCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Taipei Veterans General Hospital, TaiwanBristol-Myers SquibbCompletedProphylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B (HBVNHL)Hepatitis B | Non Hodgkin's LymphomaTaiwan